Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William H Chappell

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Advances in Enzyme Regulation|November 2, 2010
Targeting the cancer initiating cell: the Achilles' heel of cancerJames A McCubrey, William H Chappell, Stephen L Abrams, et al.
Expert Opinion on Therapeutic Targets|August 13, 2008
Akt as a therapeutic target in cancerLinda S Steelman, Kristin M Stadelman, William H Chappell, et al.
Cell Cycle (Georgetown, Tex.)|April 8, 2010
Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugsLinda S Steelman, Stephen L Abrams, John G Shelton, et al.
Advances in Biological Regulation|November 4, 2015
Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cellsWilliam H Chappell, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Oncotarget|October 27, 2012
Effects of ectopic expression of NGAL on doxorubicin sensitivityWilliam H Chappell, Stephen L Abrams, Giuseppe Montalto, et al.
Current Pharmaceutical Design|October 22, 2013
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLCLudovica Ciuffreda, Ursula Cesta Incani, Linda S Steelman, et al.
Aging|June 4, 2020
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Advances in Biological Regulation|October 6, 2020
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signalingLinda S Steelman, William H Chappell, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|May 4, 2010
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapyStephen L Abrams, Linda S Steelman, John G Shelton, et al.
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Advances in Enzyme Regulation|November 2, 2010
Targeting the cancer initiating cell: the Achilles' heel of cancerJames A McCubrey, William H Chappell, Stephen L Abrams, et al.
Expert Opinion on Therapeutic Targets|August 13, 2008
Akt as a therapeutic target in cancerLinda S Steelman, Kristin M Stadelman, William H Chappell, et al.
Cell Cycle (Georgetown, Tex.)|April 8, 2010
Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugsLinda S Steelman, Stephen L Abrams, John G Shelton, et al.
Advances in Biological Regulation|November 4, 2015
Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cellsWilliam H Chappell, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Oncotarget|October 27, 2012
Effects of ectopic expression of NGAL on doxorubicin sensitivityWilliam H Chappell, Stephen L Abrams, Giuseppe Montalto, et al.
Current Pharmaceutical Design|October 22, 2013
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLCLudovica Ciuffreda, Ursula Cesta Incani, Linda S Steelman, et al.
Aging|June 4, 2020
Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Advances in Biological Regulation|October 6, 2020
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signalingLinda S Steelman, William H Chappell, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|May 4, 2010
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapyStephen L Abrams, Linda S Steelman, John G Shelton, et al.
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Pageof 4